Literature DB >> 21567187

Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility.

Niklas Mattsson1, Shahrzad Tabatabaei, Per Johansson, Oskar Hansson, Ulf Andreasson, Jan-Eric Månsson, Jan-Ove Johansson, Bob Olsson, Anders Wallin, Johan Svensson, Kaj Blennow, Henrik Zetterberg.   

Abstract

Activated microglial cells, which are the resident macrophages of the central nervous system, surround amyloid β-plaques in Alzheimer's disease (AD) brains. Inflammation including microglial activation may contribute in AD pathogenesis, and biomarkers for this process may thus be of value to study AD pathogenesis and might facilitate development of therapies targeting these cells. We therefore examined cerebrospinal fluid (CSF) biomarkers in patients with AD, other dementias, mild cognitive impairment and in healthy controls. Samples were analyzed for markers with known association to macrophage activity, including chitotriosidase, YKL-40 (CHI3L1, HC gp-39) and chemokine CC motif ligand 2 (CCL2, MCP1). Patients with AD had higher chitotriosidase activity than controls and patients with stable mild cognitive impairment, consistent with the presence of activated microglial cells in AD brains, but with large overlaps between groups. CCL2 and YKL-40 concentrations did not differ among groups. Microglial markers are unlikely to be useful for AD diagnosis, but might be useful for identification of distinct subgroups of patients, and for the development and implementation of drugs targeting microglial pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567187     DOI: 10.1007/s12017-011-8147-9

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  42 in total

1.  Human CHIT1 gene distribution: new data from Mediterranean and European populations.

Authors:  Ignazio Piras; Alessandra Melis; Maria Elena Ghiani; Alessandra Falchi; Donata Luiselli; Pedro Moral; Laurent Varesi; Carla Maria Calò; Giuseppe Vona
Journal:  J Hum Genet       Date:  2006-11-15       Impact factor: 3.172

2.  Chitotriosidase and Alzheimer's disease.

Authors:  Stefano Sotgiu; M R Piras; Rita Barone; Giannina Arru; M L Fois; Giulio Rosati; Salvatore Musumeci
Journal:  Curr Alzheimer Res       Date:  2007-07       Impact factor: 3.498

Review 3.  Inflammation in neurodegenerative diseases.

Authors:  Sandra Amor; Fabiola Puentes; David Baker; Paul van der Valk
Journal:  Immunology       Date:  2010-02       Impact factor: 7.397

4.  Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.

Authors:  R Schiffmann; M P Heyes; J M Aerts; J M Dambrosia; M C Patterson; T DeGraba; C C Parker; G C Zirzow; K Oliver; G Tedeschi; R O Brady; N W Barton
Journal:  Ann Neurol       Date:  1997-10       Impact factor: 10.422

5.  Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro.

Authors:  L F Lue; R Rydel; E F Brigham; L B Yang; H Hampel; G M Murphy; L Brachova; S D Yan; D G Walker; Y Shen; J Rogers
Journal:  Glia       Date:  2001-07       Impact factor: 7.452

Review 6.  Research criteria for subcortical vascular dementia in clinical trials.

Authors:  T Erkinjuntti; D Inzitari; L Pantoni; A Wallin; P Scheltens; K Rockwood; G C Roman; H Chui; D W Desmond
Journal:  J Neural Transm Suppl       Date:  2000

7.  Intrathecal chitotriosidase and the outcome of multiple sclerosis.

Authors:  S Sotgiu; R Barone; G Arru; M L Fois; M Pugliatti; A Sanna; G Rosati; S Musumeci
Journal:  Mult Scler       Date:  2006-10       Impact factor: 6.312

8.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

9.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

10.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.

Authors:  Ian G McKeith
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

View more
  45 in total

Review 1.  Progress update: fluid and imaging biomarkers in Alzheimer's disease.

Authors:  Courtney L Sutphen; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2013-09-05       Impact factor: 13.382

Review 2.  Applying fluid biomarkers to Alzheimer's disease.

Authors:  Henrik Zetterberg
Journal:  Am J Physiol Cell Physiol       Date:  2017-04-19       Impact factor: 4.249

3.  Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.

Authors:  Ione O C Woollacott; Jennifer M Nicholas; Carolin Heller; Martha S Foiani; Katrina M Moore; Lucy L Russell; Ross W Paterson; Ashvini Keshavan; Jonathan M Schott; Jason D Warren; Amanda Heslegrave; Henrik Zetterberg; Jonathan D Rohrer
Journal:  Dement Geriatr Cogn Disord       Date:  2020-04-28       Impact factor: 2.959

Review 4.  Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Authors:  Alberto Lleó; Enrica Cavedo; Lucilla Parnetti; Hugo Vanderstichele; Sanna Kaisa Herukka; Niels Andreasen; Roberta Ghidoni; Piotr Lewczuk; Andreas Jeromin; Bengt Winblad; Magda Tsolaki; Barbara Mroczko; Pieter Jelle Visser; Isabel Santana; Per Svenningsson; Kaj Blennow; Dag Aarsland; José Luis Molinuevo; Henrik Zetterberg; Brit Mollenhauer
Journal:  Nat Rev Neurol       Date:  2014-12-16       Impact factor: 42.937

Review 5.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

6.  Trophoblast induces monocyte differentiation into CD14+/CD16+ macrophages.

Authors:  Paulomi B Aldo; Karen Racicot; Vinicius Craviero; Seth Guller; Roberto Romero; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2014-07-03       Impact factor: 3.886

7.  Time-Dependent Increase of Chitinase1 in APP/PS1 Double Transgenic Mice.

Authors:  Qian Xiao; Rui Shi; Wenxiu Yang; Yan Zou; Yinshi Du; Man Zhang; Weihua Yu; Yang Lü
Journal:  Neurochem Res       Date:  2016-03-02       Impact factor: 3.996

8.  Biomarkers for microglial activation in Alzheimer's disease.

Authors:  Ronald Lautner; Niklas Mattsson; Michael Schöll; Kristin Augutis; Kaj Blennow; Bob Olsson; Henrik Zetterberg
Journal:  Int J Alzheimers Dis       Date:  2011-11-01

Review 9.  Impact of Cardiovascular Hemodynamics on Cognitive Aging.

Authors:  Elizabeth E Moore; Angela L Jefferson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311

10.  Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.

Authors:  Maria L Maccecchini; Mee Young Chang; Catherine Pan; Varghese John; Henrik Zetterberg; Nigel H Greig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.